Biofrontera AG, a biopharmaceutical company based in Leverkusen, Germany, operates within the health care sector, focusing on dermatological drugs and medical cosmetics. As of November 3, 2026, the company is listed on the Xetra exchange, with its financial metrics reflecting its current market position.
As of the close of trading on November 1, 2026, Biofrontera AG’s share price stood at 3 EUR. This figure is situated between the company’s 52-week high of 5.1 EUR, recorded on September 22, 2026, and its 52-week low of 2.21 EUR, observed on June 28, 2026. These fluctuations highlight the volatility and dynamic nature of the biotechnology sector in which Biofrontera operates.
The company’s market capitalization is currently valued at 18.6 million EUR, indicating its size and financial standing within the industry. Additionally, Biofrontera AG’s price-to-earnings (P/E) ratio is 18.83, a metric that investors often use to gauge the company’s valuation relative to its earnings.
Biofrontera AG’s global operations underscore its commitment to serving patients worldwide with its specialized products in dermatology and medical cosmetics. The company’s strategic focus on these areas positions it as a key player in the biopharmaceutical landscape, addressing critical needs in skin health and aesthetics.
In summary, Biofrontera AG continues to navigate the competitive health care sector with a clear focus on innovation and patient care, as reflected in its financial metrics and market activities.
